Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.
about
Androgen receptor activation in castration-recurrent prostate cancer: the role of Src-family and Ack1 tyrosine kinasesMolecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancerSRChing for the substrates of Src.Dissecting the role of bone marrow stromal cells on bone metastases.Beyond the androgen receptor: new approaches to treating metastatic prostate cancer. Report of the 2013 Prouts Neck Prostate Cancer MeetingDiagnostic and prognostic utility of a DNA hypermethylated gene signature in prostate cancer.Yes-mediated phosphorylation of focal adhesion kinase at tyrosine 861 increases metastatic potential of prostate cancer cells.Tendencies for higher co-expression of EGFR and HER2 and downregulation of HER3 in prostate cancer lymph node metastases compared with corresponding primary tumors.Copper as a target for prostate cancer therapeutics: copper-ionophore pharmacology and altering systemic copper distribution.Src controls castration recurrence of CWR22 prostate cancer xenografts.Src promotes castration-recurrent prostate cancer through androgen receptor-dependent canonical and non-canonical transcriptional signatures.A transgenic mouse model for early prostate metastasis to lymph nodes.Successful treatment of ovarian cancer with apatinib combined with chemotherapy: A case report.SEMA3C drives cancer growth by transactivating multiple receptor tyrosine kinases via Plexin B1.Interview with Future Medicinal Chemistry's US Senior Editor, Iwao Ojima. Interview by Issac Bruce.Recent Advances in Prostate Cancer Treatment and Drug Discovery.TRAF4-mediated ubiquitination of NGF receptor TrkA regulates prostate cancer metastasis.Lestaurtinib is a potent inhibitor of anaplastic thyroid cancer cell line models
P2860
Q26866135-48EC4188-1D20-4A77-86F9-8FC9E8B94A3DQ27024775-A51635BE-EB10-4A1F-89A6-2E1F08295167Q30457060-AF9317F5-4DFB-46EF-9245-09A957B58345Q33904588-3A735A2D-22AA-4D49-9558-63CF5B754735Q34617627-4A7C596E-4F60-4F7F-B616-A0283EDFD148Q35120213-0DE2226B-65FB-472B-8AFA-6010688D6E0EQ35832949-70C413F3-CC2B-46D6-A9EA-4203CA016F5DQ36475900-07C5D91B-45FD-476E-8676-3D4F687BF799Q37392908-3A008C5D-BD55-4B2C-94EB-CD3D2AD964E8Q37481145-A6E953BA-6217-4A53-AED6-6D837B6E28B6Q37705831-1A00AE2A-3303-4646-8C95-157EA938CD60Q41864582-2D775A9D-B515-493A-8DD6-FD3F527321F4Q45711840-D9CFC1F8-7105-4CFF-801A-F755C59D1DF6Q48216846-EFAA317E-DED2-4728-9D71-C4115FC3AED4Q48409114-65FDF38E-C71B-46DE-B81F-52FB8C2534ACQ54111821-301DB694-C88C-43C7-9685-219F85123B45Q54979954-E2F907BF-70B4-45A1-B0F7-994438F41A35Q59129787-9E37133C-D291-47A7-A5C3-E2C05971AF0F
P2860
Small-molecule protein tyrosine kinase inhibitors for the treatment of metastatic prostate cancer.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Small-molecule protein tyrosin ...... of metastatic prostate cancer.
@en
Small-molecule protein tyrosin ...... of metastatic prostate cancer.
@nl
type
label
Small-molecule protein tyrosin ...... of metastatic prostate cancer.
@en
Small-molecule protein tyrosin ...... of metastatic prostate cancer.
@nl
prefLabel
Small-molecule protein tyrosin ...... of metastatic prostate cancer.
@en
Small-molecule protein tyrosin ...... of metastatic prostate cancer.
@nl
P2093
P2860
P356
P1476
Small-molecule protein tyrosin ...... of metastatic prostate cancer.
@en
P2093
Amado J Zurita
Gary E Gallick
Paul G Corn
Sue-Hwa Lin
P2860
P304
P356
10.4155/FMC.11.161
P577
2012-01-01T00:00:00Z